CD276 and neoplasm: B7H3-redirected CAR T cells could release effector cytokines, IFN-γ and IL-2, and target GBM cell lines and patient-derived neurospheres in vitro and in vivo (Nehama et al., 2019), as also reported in other tumor-related xenograft models including medulloblastoma, Ewing sarcoma, osteosarcoma (Majzner et al., 2019), AML, and melanoma (Zhang et al., 2020).